Study on N-(pyridin-4-Yl) Salicylamides as Antimycobacterial Agents

Abstract:

A series of N-(pyridin-4-yl) salicylamides derivatives were prepared through acylation of the corresponding acetylsalicyloyl chlorides with substituted 4-amino-pyridines. These compounds were evaluated in vitro for antimycobacterial activities against Mycobacterium tuberculosis (TB) and Mycobacterium avium (A) by the minimum inhibitory concentrations (MIC) values. Eight of the compounds exhibited lower MIC against A than isoniazide (INH). Meanwhile, four of the compounds exhibited good anti-TB activity, when they were compared with INH. Antimycobacterial activities of N-(pyridin-4-yl) salicylamides were influenced by the balance between hydrophobicity and electron-withdrawing substituent effect on the phenyl and pyridine ring. These studies show that these compounds might serve as prospective wide-spectrum antimycobacterial substances.

• Periodical: Advanced Materials Research (Volumes 634-638)
• Pages: 1371-1375
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.634-638.1371
• Online since: January 2013
• Authors: Zhi Jun Xin, Zhong Jia, Dian He, Jian Ping Liang, Lei Tao, Xue Hu Li, Xi Hong Lu
• Keywords: Activity Evaluation, Mycobacterium Tuberculosis, N-(pyridin-4-Yl) Salicylamides, Synthesis

References

[1] K. Waisser, J. Hladuvková and L. Kuneš: Chem. Pap Vol. 55 (2001), p.121.

[2] K. Waisser, P. Bureš and P. Holý: Arch. Pharm Vol. 336 (2003), p.53.

[3] D.J. Hlasta, J.P. Demers and B.D. Foleto: Bioorg. Med.Chem. Lett Vol. 8 (1998), 1923.

[4] J.B. Stock, A.J. Ninfa and A.M. Stock: Microbiol. Rev Vol. 53 (1989), p.450.

[5] J.A. Hoch and T.J. Silhavy: Two-component Signal Transduction, ASM Press Publications, Washington, D.C. (1995), p.305.

[6] R.A. Goldschmidt, M.J. Macielag and D. J. Hlasta: Curr. Pharm. Des Vol. 3 (1997), p.125.

[7] M. J. Macielag, J. P. Demers and S. A. Fraga-Spano: J. Med. Chem Vol. 41 (1998), p.2939.

[8] I.M. Ota and A. Varshavsky: Science, Vol. 262 (1993), p.566.

[9] K. Waisser, M. Perˇina and P. Holý: Arch. Pharm Vol. 336 (2003), p.322.

[10] K.Waisser, M. Perˇina and V. Klimešová: Collect. Czech. Chem. Commun Vol. 68 (2003), p.1275.

[11] K. Waisser, K. Dražková and J. Kuneš: IL FARMACO Vol. 59 (2004), p.615.

DOI: 10.1016/j.farmac.2004.02.003

[12] F.D. Populaire, J.O. Capobianco and D. Zakula: J. Antimicrob Chemother Vol. 41 (1998), p.179.

[13] R.C. Goldman and F. Scaglione: Curr Drug Targets Infect Disord Vol. 4 (2004), p.241.

[14] H. Zhao, J. Zhu and O. Krasnykh: Tuberculosis Vol. 88 Suppl. 1 (2008), p.549.

[15] M.Botta, M.Artico and S. Massa: Eur. J. Med. Chem Vol. 27 (1992), p.251.

[16] Chinese antituberculosis association: J. CHIN. ANTITUBERCULOSIS. Vol. 18 (1996), p.28.